Next Article in Journal
Benzimidazole Derivatives Suppress Fusarium Wilt Disease via Interaction with ERG6 of Fusarium equiseti and Activation of the Antioxidant Defense System of Pepper Plants
Previous Article in Journal
Identifying Bioactive Ingredients and Antioxidant Activities of Wild Sanghuangporus Species of Medicinal Fungi
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
JoF
Volume 9
Issue 2
10.3390/jof9020243
jof-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Emergence of Clonally-Related South Asian Clade I Clinical Isolates of Candida auris in a Greek COVID-19 Intensive Care Unit

by
Maria Katsiari
1,
Angeliki Mavroidi
2,
Nikolaos Kesesidis
3,
Eleftheria Palla
2,
Konstantina Zourla
2,
Kyriakos Ntorlis
1,
Konstantinos Konstantinidis
3,
Maria Laskou
1,
Konstantinos Strigklis
1,
Anastasios Sakkalis
1,
Charikleia Nikolaou
1,
Evangelia D. Platsouka
2,
Ioannis Karakasiliotis
3,
Georgia Vrioni
4 and
Athanasios Tsakris
4,*
1
Intensive Care Unit, Konstantopouleio-Patission General Hospital, 14233 Athens, Greece
2
Department of Microbiology, Konstantopouleio-Patission General Hospital, 14233 Athens, Greece
3
Laboratory of Biology, Department of Medicine, Democritus University of Thrace, 68100 Alexandroupolis, Greece
4
Department of Microbiology, Medical School, National and Kapodistrian University of Athens, 75 MikrasAsias Street, 11527 Athens, Greece
*
Author to whom correspondence should be addressed.
J. Fungi 2023, 9(2), 243; https://doi.org/10.3390/jof9020243
Submission received: 3 January 2023 / Revised: 5 February 2023 / Accepted: 8 February 2023 / Published: 11 February 2023
Browse Figures
Versions Notes

Abstract

:
Candida auris has recently emerged as a multidrug-resistant yeast implicated in various healthcare-associated invasive infections and hospital outbreaks. In the current study, we report the first five intensive care unit (ICU) cases affected by C. auris isolates in Greece, during October 2020–January 2022. The ICU of the hospital was converted to a COVID-19 unit on 25 February 2021, during the third wave of COVID-19 in Greece. Identification of the isolates was confirmed by Matrix Assisted Laser Desorption Ionization Time of Flight mass spectroscopy (MALDI-TOF]. Antifungal susceptibility testing was performed by the EUCAST broth microdilution method. Based on the tentative CDC MIC breakpoints, all five C. auris isolates were resistant to fluconazole (≥32 μg/mL), while three of them exhibited resistance to amphotericin B (≥2 μg/mL). The environmental screening also revealed the dissemination of C. auris in the ICU. Molecular characterization of C. auris clinical and environmental isolates was performed by MultiLocus Sequence Typing (MLST) of a set of four genetic loci, namely ITS, D1/D2, RPB1 and RPB2, encoding for the internal transcribed spacer region (ITS) of the ribosomal subunit, the large ribosomal subunit region and the RNA polymerase II largest subunit, respectively. MLST analysis showed that all isolates possessed identical sequences in the four genetic loci and clustered with the South Asian clade I strains. Additionally, PCR amplification and sequencing of the CJJ09_001802 genetic locus, encoding for the “nucleolar protein 58” that contains clade-specific repeats was performed. Sanger sequence analysis of the TCCTTCTTC repeats within CJJ09_001802 locus also assigned the C. auris isolates to the South Asian clade I. Our study confirms that C. auris is an emerging yeast pathogen in our region, especially in the setting of the ongoing COVID-19 worldwide pandemic. Adherence to strict infection control is needed to restrain further spread of the pathogen.

1. Introduction

Candidemia and other forms of invasive candidiasis, including infections of normally sterile body fluids, deep tissues and organs, are associated with prolonged hospitalization, increased health care costs and poor outcomes [1,2]. Although Candida albicans remains the most often isolated species, a shift towards Candida non-albicans species has been observed recently, which is thought to be driven mainly by the increasing use of prophylactic antifungal agents [3]. Candida auris is an emerging multidrug-resistant yeast that has been implicated in healthcare-associated outbreaks and various invasive infections. It was first reported in 2009, after being isolated from the external ear canal discharge of a patient in Japan [4]. However, C. auris was also found incidentally by molecular identification of unidentified yeasts, which were recovered in 1996 as bloodstream isolates [5]. Thereafter, cases of persistent colonization and invasive infections have been described in more than 40 countries located on six continents [6,7]. At the present time, C. auris is divided into four major clades displaying distinct biological and drug resistance patterns: I, Southern Asian; II, Eastern Asian; III, South African; IV, South American. Recently, clade V has been identified in Iran showing a difference of >200,000 single-nucleotide polymorphisms (SNPs) from the other clades [8].
There are several reasons for C. auris being a serious concern for public health. Firstly, identification of C. auris remains challenging since most phenotypic methods misidentify it. C. auris typically forms smooth, shiny, pink or whitish-gray, viscous colonies on growth media, while it has high tolerance for salinity and heat [9,10,11,12]. Nevertheless, other Candida species, such as C. haemulonii, C. duobushaemulonii and C. lusitaniae are closely related and share similar phenotypic characteristics. The most common diagnostic platforms available in clinical and public health laboratories (e.g., VITEK2) often misidentify C. auris [10,11,12,13]. Accurate identification methods for C. auris include matrix-assed laser desorption ionization-time of flight (MALDI-TOF) platforms, polymerase chain reaction, sequencing, and amplified fragment length polymorphism fingerprinting.
Moreover, C. auris exhibits a high propensity to contaminate healthcare environments, resulting in clonal transmission. Among its characteristics are the thermo- and halotolerance, along with inability to flourish in anaerobic and acidic conditions [14]. Patients shed C. auris in their close environment. C. auris contamination has been found on bed rails, bed pans, mattresses, linen, pillows, furniture, door handles, flooring, walls, radiators and windowsills, bathing areas, sinks and cleaning equipment [6,7]. Moreover, medical equipment has also been found contaminated through contact with patients. Notably, C. auris may survive for seven days on steel and porous surfaces and for 14 days on plastics, while it can further survive in anon-culturable state on plastic surfaces for up to four weeks [15,16]. Lastly, C. auris exhibits resistance to fluconazole and variable susceptibility to other azoles, amphotericin B, and echinocandins. C. auris isolates are often multidrug-resistant and there are several reports of resistant isolates to triazoles, presumably due to their abuse in marginalized populations, resistant strains to polyenes depending on the region where the strain is isolated, and echinocandin-resistant strains in India and South Africa. Although high levels of intrinsic (e.g., polyenes) and acquired resistance (e.g., azoles and echinocandins) of Candida spp. have been well documented, the knowledge of the molecular resistance mechanisms of C. auris is still unclear [17,18]. C. auris’ ability to resist to antifungal drugs, along with the inability of commonly used disinfectants in healthcare settings to eradicate C. auris, further complicate the problem.
In Greece, the first report of C. auris in 2019 involved a sporadic case of male cystic fibrosis patient in his 20s, who presented with respiratory exacerbation [19]. In the current study, we report for the first time, the dissemination of South Asian clade I C. auris isolates among patients hospitalized during a 15 month-period of the COVID-19 pandemic in a Greek multidisciplinary intensive care unit (ICU). According to our knowledge, molecular characterization of C. auris outbreaks has not been previously performed in Greece.

2. Materials and Methods

2.1. Setting, Definition of Cases, Demographic and Clinical Characteristics of C. auris Cases

“Konstantopouleio-Patission” is a tertiary care hospital in Athens, Greece (with approximately three million inhabitants), with a maximum of 280 beds in total, including: a nine-bed multidisciplinary ICU, internal medicine, cardiology, surgical, urology and other wards. The study was conducted during October 2020–January 2022 and a case was defined as any patient hospitalized in the ICU and infected with C. auris, during routine surveillance of cultures from various clinical specimens of ICU patients. The ICU of the hospital was converted to a COVID-19 unit on 25 February 2021, during the third wave of COVID-19 in Greece. Patient 1 was non-COVID-19, whereas patients 2–5 were admitted in the ICU as COVID-19 positive. It should be mentioned that all COVID-19 patients had received corticosteroid therapy with dexamethasone; patient 5 had additionally received tocilizumab. The demographic and clinical characteristics of the five ICU patients infected with C. auris are presented in Table 1.
The first patient (patient 1) was a 42-year-old man with traumatic paraplegia and diabetes mellitus, who was admitted in hospital with a6-day fever and shortly was intubated due to septic shock and lactic acidosis (Table 1). Upon ICU admission, he presented with acute respiratory distress syndrome (ARDS), severe hemodynamic instability and oliguria. He was treated for presumable urosepsis with broad spectrum antibiotics, including fluconazole, and his condition was ameliorated. On day 22, he presented new septic shock and multiple cultures were obtained. C. auris, along with other multidrug resistant pathogens (Acinetobacter baumannii, Klebsiella pneumoniae, Enterococcus faecium) from a deep hip decubitus ulcer were isolated. Concurrently, C. auris was isolated from a urine culture. The patient was then administrated with micafungin. Despite treatment, the same pathogens, including C. auris, were isolated from the hip decubitus ulcer on day 44. The patient expired on day 49, due to septic shock and multi-organ failure. Of note, no other cultures from contemporary patients, or environmental samples revealed C. auris.
Patient 2 was a 57-year-old woman with metastatic adenocarcinoma of rectum, who had undergone a nephrostomy and a ureterostomy. She was transferred to our ICU from the surgical ward of another hospital due to septic shock, lactic acidosis and acute renal failure. Upon admission, blood and urine cultures disclosed C. albicans and vancomycin-resistant E. faecium, while on day 8 multidrug resistant A. baumannii was isolated from blood cultures. On day 9, C. auris was isolated from a urine sample obtained from ureterostomy. The patient was successfully treated with meropenem, daptomycin and fluconazole and transferred to a surgical ward on day 10.
Patient 3 was a 72-year-old woman with diabetes mellitus, arterial hypertension and asthma. On day 13, C. auris was isolated from a surveillance urine culture. She received a 14-day course with caspofungin without attainment of urine sterilization. Notably, on day 28, the patient suffered from catheter-related bloodstream infection due to multidrug resistant A. baumannii, which was successfully treated with central line removal and administration of meropenem plus colistin. The patient was hospitalized in the ICU for 44 days and afterwards transferred to a rehabilitation center.
Patient 4 was a 78-year-old man with diabetes mellitus, arterial hypertension and a recently placed stent in the common bile duct due to painless jaundice. Upon admission, blood cultures disclosed vancomycin-resistant E. faecium. On day 9, C. auris and C. parapsilosis were isolated from blood samples and C. auris also in urine; thus, he was started a course of caspofungin. On day 20, amphotericin B was added due to persistence of leukopenia and mild septic condition. A computed tomography was performed and was not indicative of stent contamination. C. auris isolation in urine cultures persisted until his death (day 37).
The last patient (patient 5) was a 64-year-old woman. Her medical record included rheumatoid arthritis under treatment with prednizolone, renal resection due to adenocarcinoma for the past six years, and Hashimoto thyroiditis. On day 12, she developed septic shock due to E. faecium and A. baumannii and the antimicrobial regimen was escalated to meropenem, tigecycline and daptomycin. On day 14, C. auris was isolated from bronchial secretions, while being on itraconazole. The patient expired due to septic shock on day 20.

2.2. Culture, Identification of the Isolates, Antimicrobial Susceptibility Testing and Environmental Screening

Bacterial isolates and yeasts from various clinical specimens were identified and antimicrobial susceptibility testing was performed by the Vitek2 Compact15 automated system (Biomerieux, Paris, France) ona routine basis at the hospital clinical laboratory. Yeasts were grown on Sabouraud Dextrose agar at 35 °C and 42 °C. Additionally, CHROMagarTM Candida Plus agar was used and pale cream colonies with a distinctive blue halo, suspected as C. auris, were sent to the Department of Microbiology, Medical School, National and Kapodistrian University of Athens, Greece for further analysis. Identification of the isolates was confirmed by MALDI-TOF spectrometry, which is one of the most efficient diagnostic techniques for accurate identification of C. auris using the Microflex LT (Bruker Daltonics, Bremen, Germany) platform. Susceptibility to antifungal agents was evaluated by the European Committee on Antimicrobial Susceptibility Testing (EUCAST) standardized broth microdilution method [20] and interpretation of minimum inhibitory concentration (MIC) values was based on U.S.A. Centers for Disease Control and Prevention (CDC) proposed breakpoints [21].
The Infectious Disease Control Committee of the hospital was informed, and environmental screening was performed, when three patients (patients 2–4) were concurrently hospitalized in the ICU during August–September 2021. Cultures from three environmental samples (surface samples from beds and side tables) during this period have also yielded this pathogen.

2.3. Sequencing and Phylogenetic Analysis of C. auris Isolates

PCR amplification and sequencing of four housekeeping genetic loci of the MLST scheme used for molecular typing of C. auris were performed based on previous studies, including the internal transcribed spacer (ITS) of the ribosomal DNA (rDNA), the D1/D2 large ribosomal subunit regions, as well as RPB1 and RPB2 of the RNA polymerase II largest subunit [22,23,24]. After DNA extraction from cultivated C. auris strains from clinical and environmental samples on Sabouraud dextrose agar, the ITS region of the ribosomal subunit was amplified using the ITS-1 (5′-TCCGTAGGTGAACCTTGCGG-3′) and ITS-4 (5′-TCCTCCGCTTATTGATATGC-3′) set of primers, while the D1/D2 region was amplified using primers NL-1 (5′-GCATATCAATAAGCGGAGGAAAAG-3′) and NL-4 (5′-GGTCCGTGTTTCAAGACGG-3′). The RPB1 gene was amplified using the RPB1af (5′-GARTGYCCDGGDCAYTTYGG-3′) and RPB1cr (5′-CCNGCDATNTCRTTRTCCATRTA-3′) primers and amplification of RPB2 was performed using primers RPB2-5F (5′-GAYGAYMGWGATCAYTTYGG-3′) and RPB2-7Cr (5′-CCCATRGCTTGYTTRCCCAT-3′). All sequencing reactions were carried out using the respective forementioned primer sets. Specific genetic loci containing short tandem repeat (STR) markers can also be used to differentiate C. auris clades. PCR amplification and sequencing was performed for one of these markers, using the M9a primer pair [24]. All nucleotide sequences obtained after the PCR amplification and Sanger sequencing of each examined genetic locus were aligned by MUSCLE [25] in order to investigate the origin, clade classification and possible divergence between the studied C. auris isolates. C. auris strains from both clinical and environmental samples possessed identical sequences in the examined genetic loci.
Nucleotide ITS, D1/D2, RPB1 and RPB2 sequences of various C. auris strains were concatenated bioinformatically [26] and also included for the construction of the phylogenetic trees, as representatives of known C. auris clades according to the literature, obtained from the National Center for Biotechnology Information (NCBI) website (https://www.ncbi.nlm.nih.gov/), as follows: B11205 (CP060353-CP060359), B13916 (CP060374-CP060380), B11220 (CP043531-CP043537), B12043 (CP050666-CP050672), B11809 (CP050659-CP050665), B13463 (CP050652-CP050658), B12037 (CP060367-CP060373), B12631 (CP060360-CP060366), B17721 (CP060353-CP060359), B11245 (CP043442-CP043448), B12342 (CP060346-CP060352), and B18474 (CP050673-CP050679), BJCA001 (CP068451-CP068458), CA1LBN (CP077052-CP07705). A total of 15 nucleotide sequences and 2713 positions in the final dataset were included. All nucleotide sequences were then refined through default MUSCLE alignment, as provided by the MEGA11 software [27]. Lastly, the phylogenetic reconstruction was performed using the neighbor joining (NJ) substitution model. The bootstrap consensus tree inferred from 500 replicates was taken to represent the evolutionary history of the taxa analyzed. The evolutionary distances were computed using the Kimura 2-parameter method and are in the units of the number of base substitutions per site. Codon positions included were 1st + 2nd + 3rd + Noncoding. All ambiguous positions were removed for each sequence pair (pairwise deletion option).

3. Results

3.1. Timeline of the Five C. auris Cases in the ICU

The timeline of the five C. auris cases in the ICU is presented in Figure 1. The first patient (patient 1) was admitted in the ICU on October 2020, when the ICU was non-COVID-19. As mentioned earlier, the ICU of the hospital was converted into a COVID-19 unit on 25 February 2021. The next four patients (patients 2 to 5) were hospitalized in the ICU during August 2021–January 2022, when the ICU was COVID-19. Patients 2 to 4 were hospitalized concurrently in the ICU during August–September 2021. The last patient (patient 5) was hospitalized on January 2022, four months after the aforementioned ICU dissemination.

3.2. Antifungal Susceptibility Testing

The antifungal susceptibility testing of C. auris isolates recovered from the five ICU patients is presented in Table 2. Based on the tentative CDC MIC breakpoints for fluconazole (≥32 μg/mL), amphotericin B (≥2 μg/mL), micafungin (<4 μg/mL) and anidulafungin (<4 μg/mL), all isolates were resistant to fluconazole (MICs > 128), while three of them exhibited resistance to amphotericin B (MICs ≥ 2 μg/mL). All isolates were susceptible to micafungin (MICs 0.12–0.5) and anidulafungin (MICs 0.12–0.5).

3.3. Molecular Typing

The ITS, D1/D2, RBP1 and RPB2 genetic loci are often used for the molecular typing of Candida species, while also showing intra-species variation [22]. Sanger sequence analysis for these four genomic regions was used to investigate the phylogenetic relationships of the studied C. auris isolates and identify the cluster/clade in which they belonged. However, prior to molecular typing and phylogenetic analysis of the studied C. auris isolates, the respective ITS, D1/D2, RPB1 and RPB2 sequenced regions were aligned by MUSCLE and each output nucleotide sequence alignment demonstrated that all of the studied C. auris isolates (both clinical and environmental) possessed identical sequences. Phylogenetic analysis was performed subsequently based on the ITS, D1/D2, RPB1 and RPB2 nucleotide sequences of the isolates, which were bioinformatically fused (concatenated), as stated. The studied C. auris isolates phylogenetically clustered within clade I with a bootstrap value of 100 and were closely related with the B11205 C. auris strain from India with a bootstrap value of 52 (Figure 2). Sanger sequence analysis of the TCCTTCTTC repeats within CJJ09_001802 locus, encoding the “nucleolar protein 58” that contains clade-specific repeats, also demarcated the strain with clade I (18 repeats, clade I, Supplementary Figure S1). As the CJJ09_001802 region lacked differentiating mutations apart from the number of TCCTTCTTC repeats, the analysis could not observe phylogenetic relationships with other C. auris epidemic strains.

4. Discussion

In the present study, we reported a case-series of ICU patients with C. auris, who were hospitalized in a nine-bed Greek ICU during different time points. The first case occurred before ICU’s operation as ICU-COVID-19 and represented a single case, since no other contemporary patient, nor the environmental samples, revealed C. auris. The next three cases (patients 2–4) clustered within a 25-day period, during the fourth wave of COVID-19 occurred in Greece, when the ICU was operated as a COVID-19 ICU. The environmental screening also revealed C. auris isolates with identical sequences in the examined genetic loci, suggesting its horizontal transmission. Of note, patient 2 has been transferred in the ICU from another hospital of Athens, Greece and, according to our knowledge, this hospital was surveyed for potential C. auris contamination. The last case appeared four months later. According to MLST, all five C. auris clinical isolates belonged to clade I (clustered with South Asian strains), as the first reported case from our country [19], suggesting that this pathogen is circulating in Greece at least as of 2019. In more detail, the phylogenetic analysis based on the concatenated ITS, RPB1, RPB2 and D1/D2-nucleotide sequences of the C. auris isolates identified in the current survey and other isolates belonging to clades Ι to V has shown that all five clade I C. auris of our collection were closely related to those described from India. Moreover, antifungal susceptibility and sequence analysis results of C. auris isolates of the present study were in accordance with previous studies, as clade I has shown the greatest percentage of isolates resistant to fluconazole (97%) and amphotericin B (47%) [22].
Increasing reports of C. auris outbreaks among COVID-19 patients have been published recently [28,29,30,31]. Similarly to our cases, COVID-19 patients are usually hospitalized in ICUs for prolonged periods and receive mechanical ventilation and multiple courses of broad-spectrum antibiotics. Immune deregulation associated with COVID-19 along with treatment with anti-interleukin-6 (anti-IL-6) agents, such as tocilizumab and corticosteroids, make these patients susceptible to fungal infections [32,33]. Moreover, C. auris demonstrates high propensity to develop antifungal resistance under selective pressure [18]. Recent research has shown that most C. auris strains show higher resistance to fluconazole, followed by amphotericin B, and less resistance to 5-fluorocytosine and caspofungin [7,18,34,35,36,37]. Echinocandins are recommended as the first line empiric therapy for C. auris infections, pending susceptibility testing. In order to provide better efficacy due to synergistic interactions, combined treatment with echinocandin and liposomal amphotericin B has been prescribed in unresponsive cases to echinocandins, as in patient 1 with the soft tissue infection.
C. auris has been implicated in various infections, such as bloodstream and urinary tract infections, otitis, skin and bone infections, myocarditis and meningitis [7]. However, isolation of C. auris from non-sterile body sites, such as skin, lungs or urinary and genital tract, may not always reflect infection. Indeed, we can speculate that C. auris in patients 2, 3 and 5 rather represented colonization, since signs or symptoms of infection were not obvious at isolation time. In any case, it is crucial to identify C. auris even from a non-sterile body site because of the risk of contact transmission. Unlike other Candida species, C. auris features a propensity to colonize certain superficial body sites, such as the groin, axilla and nares, but not the intestinal tract [8,14]. On the other hand, patients who have received treatment in healthcare facilities can be persistently colonized (nares, groin, axilla, skin, urinary tract, vagina and rectum) from 1 month to 3 years, and perhaps indefinitely [8]. Similarly, in all our patients whose subsequent cultures were tested (patients 1, 3 and 4). C. auris isolation persisted until their discharge from the ICU. A substantial defense mechanism that protects C. auris against antifungals is biofilm formation. C. auris isolates are able to form either low or high biomass biofilms depending on the micro-environment, which can be highly resistant to all classes of antifungals through multiple mechanisms [34,35,36,37]. Thus, cases resistant to all available antifungals have been reported. There is currently no known decolonization strategy. Environmental cleaning is fundamental for preventing horizontal transmission within a healthcare facility. Proper disinfection of reusable medical equipment is also mandatory. Furthermore, screening should be applied for patients previously hospitalized in a healthcare environment with confirmed C. auris isolation.
However, the most alarming issue is the C. auris transmission within the ICU environment. During the COVID-19 pandemic, extended use of the underlayer protective equipment, multiple gowns and glove layers, lapses in cleaning and disinfection procedures, deficient adherence to hand hygiene by the health care personnel, along with low nurse to patient ratio, may contribute to widespread transmission of C. auris. Epidemiological investigations may elucidate the modes of C. auris nosocomial transmission. Previous studies by using MLST have shown that that C. auris strains are highly related despite being isolated from patients admitted to a large number of hospitals, suggesting that clonal strains are circulating or that the method is insufficiently discriminatory [38]. On the other hand, a microsatellite system for a largely clonal pathogen is a labor-intensive process. Whole Genome Sequence (WGS) has a high discriminatory power that may elucidate hospital transmission, although it is a costlier approach. In C. auris, whole Genome Sequence (WGS) analysis has revealed nearly simultaneous, recent and independent emergence of different clonal populations on three continents [39,40]. Several studies have utilized single nucleotide polymorphisms (SNPs), short tandem repeat, and MLST strategies for molecular typing of C. auris outbreaks. However, a standardized dataset to allow for comparisons of these molecular typing and phylogenomic pipelines has not been established for C. auris. Recently, a genomic benchmark dataset has been developed to serve as a resource to facilitate global efforts to collaborate and rapidly validate sequence analysis tools, which should be able to differentiate between the geographic clades, hospital transmission, colonization and the extent of carriage in the community [41,42].
In the present study, by using an MLST analysis and a single STR marker, we have shown that C. auris isolates obtained from clinical and environmental samples in a Greek ICU belonged to the Southeast clade I, being more related to the strain from India. Although all isolates were epidemiologically linked and possessed identical sequences, we cannot assume clonality of the isolates (i.e., belonging to a single strain), since the discriminatory power of MLST may not be sufficient to differentiate between isolates within the same clade. Moreover, C. auris from patient 1 was isolated from a non-COVID-19 patient and patient 2 has been transferred in the ICU from another hospital of Athens, suggesting different routes of transmission. Thus, a method with high discriminatory power (e.g., WGS) is required in order to investigate hospital transmission and the dissemination of isolates in Greek hospitals. In Europe, the first case of C. auris infection was imported from India in 2009, and most of C. auris isolates belong to the clade I, while a strain of the clade II was also found in Austria [43,44]. The first outbreak of C. auris in Europe occurred in a London cardio-thoracic center between April 2015 and July 2016 [7]. C. auris outbreaks have been recently reported in five European Region countries (Denmark, France, Germany, Greece and Italy), while at least two of them in Germany and Italy involved COVID-19 patients or units dedicated to the care of COVID-19 patients [45]. C. auris transmission showed interregional spread and regional endemicity in one country (Spain).

5. Conclusions

In conclusion, we demonstrated a case series of clade I C. auris isolations among patients for the first time in Greece. Although C. auris isolation might not always represent infection, it has the ability to survive in the hospital environment and enables the horizontal transmission of the organism. This was evident from the isolation of C. auris from environmental samples in the ICU. Thus, C. auris has been associated with hospital outbreaks, mainly in the ICU environment. Due to resistance against common disinfectants along with the multidrug resistance pattern to all classes of antifungals, C. auris is recognized as a serious concern for public health. Especially in the setting of the ongoing COVID-19 worldwide pandemic, a level of vigilance is warranted. Moreover, misidentification of C. auris when using common diagnostic platforms in routine can delay diagnosis. The current study has confirmed that C. auris is an emerging yeast pathogen in our region during the ongoing COVID-19 pandemic. Adherence to strict infection control is needed to restrain further spread of the pathogen.

Supplementary Materials

The following supporting information can be downloaded at: https://www.mdpi.com/article/10.3390/jof9020243/s1, Figure S1: MUSCLE (v3.8) alighnment of the CJJ09_001802 genetic locus containing short tandem repeats (STRs) of the nonanucleotide TCCTTCTTC.

Author Contributions

Conceptualization, A.T., A.M., G.V. and M.K.; methodology, A.S., C.N., E.P., E.D.P., I.K., K.K., K.Z., K.N., M.L., K.S. and N.K.; formal analysis, investigation and writing-original draft preparation, G.V. M.K. and A.M.; writing—review, editing, and supervision, A.T. All authors have read and agreed to the published version of the manuscript.

Funding

This research received no external funding.

Institutional Review Board Statement

Ethical review and approval for the study were in accordance to the Ethics Regulations of the hospital (Act 29321/02-11-2021).

Informed Consent Statement

Patients’ consent was waived due to retrospective nature of this study. The anonymity of the patients was guaranteed during the whole process of data analysis and results reporting.

Data Availability Statement

The consensus nucleotide sequences of the ITS, D1/D2 RPB1, RPB2 and the genetic locus containing short tandem repeats (STRs) of the nonanucleotide TCCTTCTTC were deposited to GenBank database of NCBI and can be accessed online using their accession numbers (OP974692, OL455790, OL539420, OP981544and OP066795 respectively). All files related to the phylogenetic analysis of the studied C. auris isolates were uploaded to a custom Github repository (https://github.com/konskons11/Candida-auris, last accessed on 9 December 2022).

Conflicts of Interest

The authors declare no conflict of interest.

References

  1. Pfaller, M.; Diekema, D.J.; Turnidge, J.D.; Castanheira, M.; Jones, R.N. Twenty Years of the SENTRY Antifungal Surveillance Program: Results for Candida Species from 1997–2016. Open Forum. Infect. Dis. 2019, 6, 79–94. [Google Scholar] [CrossRef]
  2. Lockhart, S.R. Current Epidemiology of Candida Infection. Clin. Microbiol. Newsl. 2014, 36, 131–136. [Google Scholar] [CrossRef]
  3. Chi, H.-W.; Yang, Y.-S.; Shang, S.-T.; Chen, K.-H.; Yeh, K.-M.; Chang, F.-Y.; Lin, J.-C. Candida Albicans versus Non-Albicans Bloodstream Infections: The Comparison of Risk Factors and Outcome. J. Microbiol. Immunol. Infect 2011, 44, 369–375. [Google Scholar] [CrossRef] [PubMed]
  4. Satoh, K.; Makimura, K.; Hasumi, Y.; Nishiyama, Y.; Uchida, K.; Yamaguchi, H. Candida Auris Sp. Nov., a Novel Ascomycetous Yeast Isolated from the External Ear Canal of an Impatient in a Japanese Hospital. Microbiol. Immunol. 2009, 53, 41–44. [Google Scholar] [CrossRef]
  5. Lee, W.G.; Shin, J.H.; Uh, Y. First Three Reported Cases of Nosocomial Fungemia Caused by Candida Auris. J. Clin. Microbiol. 2011, 49, 3139–3142. [Google Scholar] [CrossRef] [PubMed]
  6. U.S.A. Centers for Disease Control and Prevention (CDC). Candida Auris: A Drug-Resistant Germ That Spreads in Healthcare Facilities. Available online: https://www.cdc.gov/fungal/candida-auris/c-auris-drug-resistant.html#:~:text=auris%20has%20caused%20outbreaks%20in,on%20surfaces%20for%20several%20weeks (accessed on 4 February 2022).
  7. Cortegiani, A.; Misseri, G.; Fasciana, T.; Giammanco, A.A.G.; Chowdhary, A. Epidemiology, Clinical Characteristics, Resistance, and Treatment of Infections by Candida Auris. J. Intensive Care 2018, 6, 69. [Google Scholar] [CrossRef]
  8. Spruijtenburg, B.; Badali, H.; Abastabar, M.; Mirhendi, H.; Khodavaisy, S.; Sharifisooraki, J.; Taghizadeh Armaki, M.; de Groot, T.; Meis, J.F. Confirmation of fifth Candida auris clade by whole genome sequencing. Emerg. Microbes Infect. 2022, 11, 2405–2411. [Google Scholar] [CrossRef]
  9. Cendejas-Bueno, E.; Kolecka, A.; Alastruey-Izquierdo, A.; Theelen, B.; Groenewald, M.; Kostrzewa, M.; Cuenca-Estrella, M.; Gómez-López, A.; Boekhout, T. Reclassification of the Candida haemulonii complex as Candida haemulonii (C. haemulonii group I), C. duobushaemulonii sp. nov. (C. haemulonii group II), and C. haemulonii var. vulnera var. nov.: Three multiresistant human pathogenic yeasts. J. Clin. Microbiol. 2012, 50, 3641–3651. [Google Scholar] [CrossRef]
  10. Kathuria, S.; Singh, P.K.; Sharma, C. Multidrug-Resistant Candida Auris Misidentified as Candida Haemulonii: Characterization by Matrix-Assisted Laser Desorption Ionization-Time of Flight Mass Spectrometry and DNA Sequencing and Its Antifungal Susceptibility Profile Variability by Vitek 2, CLSI Broth Microdilution, and Etest Method. J. Clin. Microbiol. 2015, 53, 1823–1830. [Google Scholar]
  11. Borman, A.M.; Szekely, A.; Johnson, E.M. Comparative Pathogenicity of United Kingdom Isolates of the Emerging Pathogen Candida Auris and Other Key Pathogenic Candida Species. mSphere 2016, 1, e00189-16. [Google Scholar] [CrossRef]
  12. Kim, T.H.; Kweon, O.J.; Kim, H.R.; Lee, M.K. Identification of uncommon Candida species using commercial identification system. J. Microbiol. Biotechnol. 2016, 26, 2206–2213. [Google Scholar] [CrossRef] [PubMed]
  13. Kordalewska, M.; Zhao, Y.; Lockhart, S.R.; Chowdhary, A.; Berrio, I.; Perlin, D.S. Rapid and Accurate Molecular Identification of the Emerging Multidrug-Resistant Pathogen Candida Auris. J. Clin. Microbiol. 2017, 55, 2445–2452. [Google Scholar] [CrossRef]
  14. Day, A.M.; McNiff, M.M.; Silva Dantas, A.; Gow, N.A.R.; Quinn, J. Hog1 Regulates Stress Tolerance and Virulence in the Emerging Fungal Pathogen Candida Auris. mSphere 2018, 3, e00506-18. [Google Scholar] [CrossRef]
  15. Welsh, R.M.; Bentz, M.L.; Shams, A.; Houston, H.; Lyons, A. Survival, Persistence, and Isolation of the Emerging Multidrug-Resistant Pathogenic Yeast Candida Auris on a Plastic Health Care Surface. J. Clin. Microbiol. 2017, 55, 2996–3005. [Google Scholar] [CrossRef]
  16. Cadnum, J.L.; Shaikh, A.A.; Piedrahita, C.T. Effectiveness of Disinfectants against Candida Auris and Other Candida Species. Infect. Control. Hosp. Epidemiol. 2017, 38, 1240–1243. [Google Scholar] [CrossRef]
  17. Kean, R.; Ramage, G. Combined Antifungal Resistance and Biofilm Tolerance: The Global Threat of Candida Auris. mSphere 2019, 4, e00458-19. [Google Scholar] [CrossRef]
  18. Frías-De-León, M.G.; Hernàndez-Castro, R.; Vite-Garín, T.; Srens, R.; Bonifaz, A.; Castaňő-Olivares, L.; Acosta-Altamirano, G.; Martinez-Herrera, E. Antifungal resistance in Candida auris: Molecular determinants. Antibiotics 2020, 9, 568. [Google Scholar] [CrossRef]
  19. Stathi, A.; Loukou, I.; Kirikou, H.; Petrocheilou, A.; Moustaki, M.; Velegraki, A.; Zachariadou, L. Isolation of Candida Auris from Cystic Fibrosis Patient, Greece, April 2019. Eur. Surveill. 2019, 24, 1900400. [Google Scholar]
  20. European Committee on Antimicrobial Susceptibility Testing (EUCAST) Breakpoint Tables for Interpretation of MICs for Antifungal Agents Version 10.0. Available online: https://www.eucast.org/fileadmin/src/media/PDFs/EUCAST_files/AFST/Clinical_breakpoints/AFST_BP_v10.0_200204_updatd_links_200924.pdf (accessed on 4 February 2022).
  21. U.S.A. Centers for Disease Control and Prevention (CDC). Candida auris Antifungal Susceptibility Testing and Interpretation. Available online: https://www.cdc.gov/fungal/candida-auris/c-auris-antifungal.html (accessed on 9 December 2022).
  22. Prakash, A.; Sharma, C.; Singh, A.; Kumar Singh, P.; Kumar, A.; Hagen, F.; Govender, N.P.; Colombo, A.L.; Meis, J.F.; Chowdhary, A. Evidence of Genotypic Diversity among Candida Auris Isolates by Multilocus Sequence Typing, Matrix-Assisted Laser Desorption Ionization Time-of-Flight Mass Spectrometry and Amplified Fragment Length Polymorphism. Clin. Microbiol. Infect 2016, 22, 277.e1–e9. [Google Scholar] [CrossRef]
  23. Kumar, M.; Shukla, P.K. Use of PCR Targeting of Internal Transcribed Spacer Regions and Single-Stranded Conformation Polymorphism Analysis of Sequence Variation in Different Regions of rRNA Genes in Fungi for Rapid Diagnosis of Mycotic Keratitis. J. Clin. Microbiol. 2005, 43, 662–668. [Google Scholar] [CrossRef] [PubMed]
  24. de Groot, T.; Puts, Y.; Berrio, I.; Chowdhary, A.; Meis, J.F. Development of Candida Auris Short Tandem Repeat Typing and Its Application to a Global Collection of Isolates. mBio 2020, 11, e02971-19. [Google Scholar] [CrossRef]
  25. Edgar, R.C. MUSCLE: Multiple Sequence Alignment with High Accuracy and High Throughput. Nucleic Acids Res. 2004, 32, 1792–1797. [Google Scholar] [CrossRef] [Green Version]
  26. Vaidya, G.; Lohman, D.J.; Meier, R. Sequence Matrix: Concatenation Software for the Fast Assembly of Multi-Gene Datasets with Character Set and Codon Information. Cladistics 2011, 27, 171–180. [Google Scholar] [CrossRef]
  27. Tamura, K.; Stecher, G.; Kumar, S. MEGA11: Molecular Evolutionary Genetics Analysis Version 11. Mol. Biol. Evol. 2021, 38, 3022–3027. [Google Scholar] [CrossRef] [PubMed]
  28. Villanueva-Lozano, H.; Treviño-Rangel, R.J.; González, G.M.; Ramírez-Elizondo, M.T.; Lara-Medrano, R.; Aleman-Bocanegra, M.C.; Guajardo-Lara, C.E.; Gaona-Chávez, N.; Castilleja-Leal, F.; Torre-Amione, G.; et al. Outbreak of Candida auris infection in a COVID-19 hospital in Mexico. Clin. Microbiol. Infect. 2021, 27, 813–816. [Google Scholar] [CrossRef]
  29. Di Pilato, V.; Codda, G.; Ball, L.; Giacobbe, D.R.; Willison, E.; Mikulska, M.; Magnasco, L.; Crea, F.; Vena, A.; Pelosi, P.; et al. Molecular epidemiological investigation of a nosocomial cluster of C. auris: Evidence of recent emergence in Italy and ease of transmission during the COVID-19 pandemic. J. Fungi 2021, 7, 140. [Google Scholar] [CrossRef] [PubMed]
  30. Allaw, F.; Kara Zahreddine, N.; Ibrahim, A.; Tannous, J.; Taleb, H.; Bizri, A.R.; Dbaibo, G.; Kanj, S.S. First Candida auris outbreak during a COVID-19 pandemic in a tertiary-care center in Lebanon. Pathogens 2021, 10, 157. [Google Scholar] [CrossRef]
  31. Prestel, C.; Anderson, E.; Forsberg, K.; Lyman, M.; de Perio, M.A.; Kuhar, D.; Edwards, K.; Rivera, M.; Shugart, A.; Walters, M.; et al. Candida auris outbreak in a COVID-19 specialty care unit-Florida, July–August 2020. Morb. Mortal. Wkly. Rep. 2021, 70, 56–57. [Google Scholar] [CrossRef] [PubMed]
  32. Somers, E.C.; Eschenauer, G.A.; Troost, J.P.; Golob, J.L.; Gandhi, T.N.; Wang, L.; Zhou, N.; Petty, L.A.; Baang, J.H.; Dillman, N.O.; et al. Tocilizumab for treatment of mechanically ventilated patients with COVID-19. Clin. Infect. Dis. 2020, 73, e445–e454. [Google Scholar] [CrossRef]
  33. The RECOVERY Collaborative Group. Dexamethasone in hospitalized patients with COVID-19. N. Engl. J. Med. 2021, 384, 693–704. [Google Scholar] [CrossRef]
  34. Ostrowsky, B.; Greenko, J.; Adams, E.; Quinn, M.; O'Brien, B.; Chaturvedi, V.; Berkow, E.; Vallabhaneni, S.; Forsberg, K.; Chaturvedi, S.; et al. Candida auris Isolates Resistant to Three Classes of Antifungal Medications—New York, 2019. MMWR Morb. Mortal. Wkly. Rep. 2020, 10, 6–9. [Google Scholar] [CrossRef] [PubMed]
  35. Chowdhary, A.; Voss, A.; Meis, J.F. Multidrug-Resistant Candida Auris: “New Kid on the Block” in Hospital-Associated Infections? J. Hosp. Infect. 2016, 94, 209–212. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  36. Chowdhary, A.; Sharma, A. The lurking scourge of multidrug resistant Candida auris in times of COVID-19 pandemic. J. Glob. Antimicrob. Resist. 2020, 22, 175–176. [Google Scholar] [CrossRef]
  37. Allert, S.; Schulz, D.; Kämmer, P.; Großmann, P.; Wolf, T.; Schäuble, S.; Panagiotou, G.; Brunke, S.; Hube, B. From Environmental Adaptation to Host Survival: Attributes That Mediate Pathogenicity of Candida Auris. Virulence 2022, 13, 191–194. [Google Scholar] [CrossRef]
  38. Magobo, R.; Mhlanga, M.; Corcoran, C.; Govender, N.P. Multilocus sequence typing of azole-resistant Candida auris strains, South Africa. S. Afr. J Infect. Dis. 2020, 35, 116. [Google Scholar] [CrossRef]
  39. Lockhart, S.R.; Etienne, K.A.; Vallabhaneni, S.; Farooqi, J.; Chowdhary, A.; Govender, N.P.; Colombo, A.L.; Calvo, B.; Cuomo, C.A.; Desjardins, C.A.; et al. Simultaneous Emergence of Multidrug-Resistant Candida auris on 3 Continents Confirmed by Whole-Genome Sequencing and Epidemiological Analyses. Clin. Infect. Dis. 2017, 15, 134–140. [Google Scholar] [CrossRef]
  40. Sharma, C.; Kumar, N.; Pandey, R.; Meis, J.F.; Chowdhary, A. Whole genome sequencing of emerging multidrug resistant Candida auris isolates in India demonstrates low genetic variation. New Microbes New Infect. 2016, 13, 77–82. [Google Scholar] [CrossRef]
  41. Rhodes, J.; Fisher, M.C. Global epidemiology of emerging Candida auris. Curr. Opin. Microbiol. 2019, 52, 84–89. [Google Scholar] [CrossRef]
  42. Welsh, R.M.; Misas, E.; Forsberg, K.; Lyman, M.; Chow, N.A. Candida auris Whole-Genome Sequence Benchmark Dataset for Phylogenomic Pipelines. J. Fungi 2021, 16, 214. [Google Scholar] [CrossRef]
  43. Sanyaolu, A.; Okorie, C.; Marinkovic, A.; Abbasi, A.F.; Prakash, S.; Mangat, J.; Hosein, Z.; Haider, N.; Chan, J. Candida auris: An Overview of the Emerging Drug-Resistant Fungal Infection. Infect. Chemother. 2022, 54, 236–246. [Google Scholar] [CrossRef] [PubMed]
  44. Desoubeaux, G.; Coste, A.T.; Imbert, C.; Hennequin, C. Overview about Candida auris: What's up 12 years after its first description? J. Mycol. Med. 2022, 32, 101248. [Google Scholar] [CrossRef] [PubMed]
  45. Kohlenberg, A.; Monnet Dominique, L.; Plachouras, D.; Candida auris survey collaborative group. Increasing Number of Cases and Outbreaks caused by Candida auris in the EU/EEA, 2020 to 2021. Eur. Surveill. 2022, 27, pii=2200846. [Google Scholar] [CrossRef] [PubMed]
Jof 09 00243 g001 550
Figure 1. Timeline of the five C. auris cases in the ICU. The boxes denote the length of stay (LOS) of C. auris cases in the ICU prior (grey boxes) and post to (black boxes) the isolation of C. auris. The black line denotes the period that the ICU has been functioned as a COVID-19 ICU.
Figure 1. Timeline of the five C. auris cases in the ICU. The boxes denote the length of stay (LOS) of C. auris cases in the ICU prior (grey boxes) and post to (black boxes) the isolation of C. auris. The black line denotes the period that the ICU has been functioned as a COVID-19 ICU.
Jof 09 00243 g001
Jof 09 00243 g002 550
Figure 2. Evolutionary relationships based on the concatenated ITS, RPB1, RPB2 and D1/D2-nucleotide sequences of the C. auris isolates identified in this study and other strains belonging to clades Ι to V. The identifier C. auris strain names and countries of isolation are depicted. Branches corresponding to partitions reproduced in less than 50% bootstrap replicates were collapsed. The percentage of replicate trees in which the associated taxa clustered together in the bootstrap test (500 replicates) are shown next to the branches.
Figure 2. Evolutionary relationships based on the concatenated ITS, RPB1, RPB2 and D1/D2-nucleotide sequences of the C. auris isolates identified in this study and other strains belonging to clades Ι to V. The identifier C. auris strain names and countries of isolation are depicted. Branches corresponding to partitions reproduced in less than 50% bootstrap replicates were collapsed. The percentage of replicate trees in which the associated taxa clustered together in the bootstrap test (500 replicates) are shown next to the branches.
Jof 09 00243 g002
Table
Table 1. Demographic and clinical characteristics of ICU patients with C. auris.
Table 1. Demographic and clinical characteristics of ICU patients with C. auris.
C. auris CasesCOVID-19 StatusAdmission
Date		GenderCo-MorbiditiesAgeApache II ScoreICU Day at C. auris IsolationLOS (Days)ICU
Outcome
Patient-1Negative19 October 2020Maleparaplegia, diabetes mellitus42172249Death
Patient-2Positive1 August 2021Femalemetastatic adenocarcinoma of rectum (nephrostomy, ureterostomy)5723910Survival
Patient-3Positive10 August 2021Femalediabetes mellitus, arterial hypertension, asthma72181344Survival
Patient-4Positive26 August 2021Malediabetes mellitus, arterial hypertension, painless jaundice (recently placed stent in the common bile)7812937Death
Patient-5Positive22 December 2021Femalerheumatoid arthritis, renal resection (adenocarcinoma 6 years ago), Hashimoto thyroiditis64151420Death
Table
Table 2. Antifungal susceptibility of C. auris clinical isolates.
Table 2. Antifungal susceptibility of C. auris clinical isolates.
C. auris CasesDate of Isolation ofSource of SpecimenMIC (μg/mL) of Antifungal Agents
AMPHB 15-FLUCFLU 1VORPOSMICFANDITR
Patient-130 November 2020Deep hip decubitus Ulcer/urine1<0.0625>256>8>80.120.122
Patient-223 August 2021Urine10.12>128>80.50.50.51
Patient-31 September 2021Urine2<0.0625>12880.250.120.120.5
Patient-413 September 2021Blood/
Urine		20.12>1280.50.250.120.120.25
Patient-513 January 2022Bronchial aspirate20.12>1280.120.120.250.250.06
AMPHB: AmphotericinB, 5-FLUC: 5-Flucytocine, FLU: Fluconazole, VOR: Voriconazole, POS: Posaconazole, MICF: Micafungin, AND: Anidulafungin, ITR: Itraconazole. 1 MIC values of resistant isolates are denoted in bold.
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Katsiari, M.; Mavroidi, A.; Kesesidis, N.; Palla, E.; Zourla, K.; Ntorlis, K.; Konstantinidis, K.; Laskou, M.; Strigklis, K.; Sakkalis, A.; et al. Emergence of Clonally-Related South Asian Clade I Clinical Isolates of Candida auris in a Greek COVID-19 Intensive Care Unit. J. Fungi 2023, 9, 243. https://doi.org/10.3390/jof9020243

AMA Style

Katsiari M, Mavroidi A, Kesesidis N, Palla E, Zourla K, Ntorlis K, Konstantinidis K, Laskou M, Strigklis K, Sakkalis A, et al. Emergence of Clonally-Related South Asian Clade I Clinical Isolates of Candida auris in a Greek COVID-19 Intensive Care Unit. Journal of Fungi. 2023; 9(2):243. https://doi.org/10.3390/jof9020243

Chicago/Turabian Style

Katsiari, Maria, Angeliki Mavroidi, Nikolaos Kesesidis, Eleftheria Palla, Konstantina Zourla, Kyriakos Ntorlis, Konstantinos Konstantinidis, Maria Laskou, Konstantinos Strigklis, Anastasios Sakkalis, and et al. 2023. "Emergence of Clonally-Related South Asian Clade I Clinical Isolates of Candida auris in a Greek COVID-19 Intensive Care Unit" Journal of Fungi 9, no. 2: 243. https://doi.org/10.3390/jof9020243

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop